Abstract
The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii. Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani-infected mice but was less effective against T. gondii-infected mice.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Alendronate / pharmacology
-
Alkyl and Aryl Transferases / antagonists & inhibitors*
-
Animals
-
Cricetinae
-
Diphosphonates / administration & dosage
-
Diphosphonates / therapeutic use*
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / therapeutic use*
-
Female
-
Geranyltranstransferase
-
Injections, Intraperitoneal
-
Leishmania donovani / drug effects*
-
Leishmania donovani / enzymology*
-
Leishmaniasis, Visceral / drug therapy*
-
Leishmaniasis, Visceral / parasitology*
-
Mesocricetus
-
Mice
-
Mice, Inbred BALB C
-
Prodrugs / pharmacology
-
Survival Analysis
-
Toxoplasma / drug effects*
-
Toxoplasma / enzymology*
-
Toxoplasmosis, Animal / drug therapy*
-
Toxoplasmosis, Animal / parasitology*
Substances
-
Diphosphonates
-
Enzyme Inhibitors
-
Prodrugs
-
Alkyl and Aryl Transferases
-
Geranyltranstransferase
-
Alendronate